BAY73-4506 Probe Substrate Study
* To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of CYP 2C8 (rosiglitazone)
* To evaluate safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of BAY73-4506 in patients with advanced solid tumors
Neoplasms
DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Warfarin|DRUG: Omeprazole|DRUG: Midazolam|DRUG: Rosiglitazone
Pharmacokinetics of probe substrates (AUC, Cmax, etc.), Approximately 6 weeks
Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1), Up to 3 years or longer if indicated|Adverse event collection, Up to 3 years or longer if indicated
* To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of CYP 2C8 (rosiglitazone)
* To evaluate safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of BAY73-4506 in patients with advanced solid tumors